title: Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.
abstract: Multicentric Castleman disease (MCD) is an uncommon lymphoproliferative disorder for which the best therapeutic option is not yet well established. Immune-related disorders are rare complications of MCD. We report on an MCD case in a 23-year-old patient with extensive abdominal involvement and associated immune hemolytic anemia and Raynaud phenomenon. He was negative for human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8). After 8 courses of the anti-CD20 monoclonal antibody (rituximab), the patient achieved complete remission. Interestingly, Raynaud phenomenon disappeared under treatment and no new hemolytic events occurred. Anti-CD20 antibody treatment could be an attractive therapeutic approach for MCD, mainly when immune-related disorders are associated.
authors.affiliation: Servicio de Hematologia, Hospital Universitario de Salamanca, Spain. emocio@usal.es
authors.forename: Enrique M
authors.initials: EM
authors.lastname: Ocio
authors.forename: Fermin M
authors.initials: FM
authors.lastname: Sanchez-Guijo
authors.forename: Maria
authors.initials: M
authors.lastname: Diez-Campelo
authors.forename: Cristina
authors.initials: C
authors.lastname: Castilla
authors.forename: Oscar J
authors.initials: OJ
authors.lastname: Blanco
authors.forename: Dolores
authors.initials: D
authors.lastname: Caballero
authors.forename: Jesus F
authors.initials: JF
authors.lastname: San Miguel
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005871:Castleman Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab